Page last updated: 2024-11-10

via 2291

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

atreleuton: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3086671
CHEMBL ID59356
SCHEMBL ID2108309
MeSH IDM0547327

Synonyms (43)

Synonym
atreleuton
{3-[5-(4-fluoro-benzyl)-thiophen-2-yl]-1-methyl-prop-2-ynyl}-hydroxy urea
(r)-(+)-n-{3-[5-(4-fluorobenzyl)thien-2-yl]-1-methylprop-2-ynyl}-n-hydroxyurea
n-{(1r)-3-[5-(4-fluorobenzyl)thien-2-yl]-1-methylprop-2-ynyl}-n-hydroxyurea
bdbm50029781
n-{(1r)-3-[5-(4-fluorobenzyl)thien-2-yl]-1-methylprop-2-ynyl}-n-hydroxyurea (abt-761)
154355-76-7
atreleuton (usan/inn)
D03010
abt-761
abbott-85761
a-85761.0
CHEMBL59356 ,
a-85761
via-2291
1-[(2r)-4-[5-[(4-fluorophenyl)methyl]thiophen-2-yl]but-3-yn-2-yl]-1-hydroxyurea
unii-u301t88e1m
1-((r)-3-(5-(p-fluorobenzyl)-2-thienyl)-1-methyl-2-propynyl-1-hydroxyurea
atreleuton [usan:inn]
abt 761
via 2291
((r)-3-(5-(p-fluorobenzyl)-2-thienyl)-1-methyl-2-propynyl-1-hydroxyurea
u301t88e1m ,
via2291
1-((r)-3-(5-(p-fluorobenzyl)-2-thienyl)-1-methyl-2-propynyl)-1-hydroxyurea
atreleuton [who-dd]
atreleuton [inn]
atreleuton [usan]
(r)-n-(3-(5-(4-fluorobenzyl) thien-2-yl)-1-methyl-2-propyn- yl)-n-hydroxy-urea
(r)-n-{3-[5-(4-fluorophenylmethyl)thien-2-yl]-1-methyl-2-propynyl)-n-hydroxyurea
(r)-n-{3-[5-(4-fluorophenylmethyl)thien-2-yl]-1-methyl-2-propynyl}-n-hydroxyurea
MMSNEKOTSJRTRI-LLVKDONJSA-N
SCHEMBL2108309
DTXSID10165598
DB12758
NCGC00487341-02
CS-0068291
HY-117853
nsc-781026
nsc781026
Q27290616
1-[(2r)-4-[5-[(4-fluorophenyl)methyl]thiophen-2-yl]but-3-yn-2-yl]-1-hydroxy-urea
AKOS040741178

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Mean terminal half-life and apparent volume of distribution during the terminal elimination phase of ABT-761 ranged from 15."( Pharmacokinetics and pharmacodynamics of single and multiple oral doses of a novel 5-lipoxygenase inhibitor (ABT-761) in healthy volunteers.
Awni, WM; Chang, M; Drajesk, J; Hansen, R; Lanni, C; Witt, G; Wong, SL, 1998
)
0.3
" Mean Cmax and AUC values for norgestrel decreased by 12% and 10%, respectively, when administered with ABT-761."( Effects of ABT-761, a novel 5-lipoxygenase inhibitor, on the pharmacokinetics of a single dose of ethinyl estradiol and levonorgestrel in healthy female volunteers.
Awni, WM; Dube, LM; O'Dea, RF; Wong, SL, 1998
)
0.3
" Body weight, age, and body surface area were virtually identical in explaining the variability in dose-normalized Cmax and AUC values (R2=0."( Pharmacokinetics of a novel 5-lipoxygenase inhibitor (ABT-761) in pediatric patients with asthma.
Awni, WM; Chang, M; Drajesk, J; Dube, LM; Kearns, GL; Kemp, JP; Locke, CS; Wong, SL,
)
0.13
" The pharmacokinetic parameters of theophylline after administration of theophylline alone and concomitantly with ABT-761 were compared using a paired t-test."( Lack of cytochrome P450 1A2 interaction effect of ABT-761 on the pharmacokinetics of theophylline.
Awni, WM; Cavanaugh, JH; Hansen, R; Qian, J; Wong, SL, 1998
)
0.3

Bioavailability

ExcerptReferenceRelevance
" ABT-761 has shown excellent oral bioavailability and an extended duration of plasma levels in man, and initial results for a single 200 mg po dose have shown a significant protective effect against exercise- and adenosine-induced bronchoconstriction in asthmatics [215839]."( ABT-761 (Abbott).
Reid, JJ, 2001
)
0.31
" Crossover design was also used to evaluate oral bioavailability of ABT-761 hemihydrate formulations in beagle dogs."( Effect of physicochemical and formulation variables on the in vivo absorption of ABT-761.
Briskin, J; Fort, JJ; Gerhardt, AH; Mayer, P; Qiu, Y; Schilling, RJ; Trivedi, J, 2002
)
0.31

Dosage Studied

ExcerptRelevanceReference
" Body weight, age, or body surface area can be used to provide dosing adjustment for ABT-761 in pediatric patients."( Pharmacokinetics of a novel 5-lipoxygenase inhibitor (ABT-761) in pediatric patients with asthma.
Awni, WM; Chang, M; Drajesk, J; Dube, LM; Kearns, GL; Kemp, JP; Locke, CS; Wong, SL,
)
0.13
" ABT-761 is the follow-up compound for zileuton and, due to its increased potency, requires only once-daily dosing [187700]."( ABT-761 (Abbott).
Reid, JJ, 2001
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)IC50 (µMol)0.09000.00011.68479.3200AID1724853
Polyunsaturated fatty acid 5-lipoxygenaseRattus norvegicus (Norway rat)IC50 (µMol)0.02300.00462.018210.0000AID7057
Bifunctional epoxide hydrolase 2Homo sapiens (human)IC50 (µMol)2.70000.00000.54509.1000AID1724852
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (38)

Processvia Protein(s)Taxonomy
negative regulation of endothelial cell proliferationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukocyte chemotaxis involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukocyte migration involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene production involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene metabolic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
humoral immune responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of angiogenesisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of bone mineralizationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
dendritic cell migrationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
glucose homeostasisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
long-chain fatty acid biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of fat cell differentiationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of insulin secretionPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of vascular wound healingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of wound healingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of inflammatory response to woundingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of cytokine production involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of cellular response to oxidative stressPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene A4 biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of response to endoplasmic reticulum stressPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of sprouting angiogenesisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of leukocyte adhesion to arterial endothelial cellPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipoxin biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
response to toxic substanceBifunctional epoxide hydrolase 2Homo sapiens (human)
positive regulation of gene expressionBifunctional epoxide hydrolase 2Homo sapiens (human)
dephosphorylationBifunctional epoxide hydrolase 2Homo sapiens (human)
cholesterol homeostasisBifunctional epoxide hydrolase 2Homo sapiens (human)
stilbene catabolic processBifunctional epoxide hydrolase 2Homo sapiens (human)
phospholipid dephosphorylationBifunctional epoxide hydrolase 2Homo sapiens (human)
regulation of cholesterol metabolic processBifunctional epoxide hydrolase 2Homo sapiens (human)
epoxide metabolic processBifunctional epoxide hydrolase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (14)

Processvia Protein(s)Taxonomy
arachidonate 5-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonate 12(S)-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
iron ion bindingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
protein bindingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
hydrolase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
magnesium ion bindingBifunctional epoxide hydrolase 2Homo sapiens (human)
epoxide hydrolase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
toxic substance bindingBifunctional epoxide hydrolase 2Homo sapiens (human)
phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
10-hydroxy-9-(phosphonooxy)octadecanoate phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
lipid phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
protein homodimerization activityBifunctional epoxide hydrolase 2Homo sapiens (human)
lysophosphatidic acid phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
extracellular regionPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
extracellular spacePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelopePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelope lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nucleoplasmPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
cytosolPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear matrixPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear membranePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
secretory granule lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
perinuclear region of cytoplasmPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
ficolin-1-rich granule lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelopePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
peroxisomeBifunctional epoxide hydrolase 2Homo sapiens (human)
peroxisomal matrixBifunctional epoxide hydrolase 2Homo sapiens (human)
cytosolBifunctional epoxide hydrolase 2Homo sapiens (human)
extracellular exosomeBifunctional epoxide hydrolase 2Homo sapiens (human)
peroxisomeBifunctional epoxide hydrolase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (28)

Assay IDTitleYearJournalArticle
AID166410Compound was tested for in vitro inhibition against broken RBL-1.1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Modulators of leukotriene biosynthesis and receptor activation.
AID18431Oral bioavailability was determined in dog1995Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
(R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl- 2-propynyl]-N-hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor.
AID180524In vivo rat anaphylaxis leukotriene formation on an oral dose of 200 micro mol/Kg1997Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitors.
AID92880Inhibition of 5-lipoxygenase (5-LO) measured as LTB4 production in human whole blood stimulated with calcium ionophore (A23187).1997Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitors.
AID92725Compound was tested for in vitro inhibition against human whole blood.1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Modulators of leukotriene biosynthesis and receptor activation.
AID1724857Solubility in pH 7.4 DPBS buffer2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Design, Synthesis, and Structure-Activity Relationship Studies of Dual Inhibitors of Soluble Epoxide Hydrolase and 5-Lipoxygenase.
AID18432Oral bioavailability was determined in guinea pig1995Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
(R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl- 2-propynyl]-N-hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor.
AID69705-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4)1995Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
(R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl- 2-propynyl]-N-hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor.
AID126490Rate of glucuronidation was determined using a microsomal preparation from the monkey liver tissue1995Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
(R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl- 2-propynyl]-N-hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor.
AID177815Compound was evaluated in vivo for the rat anaphylaxis leukotriene formation at an oral dose of 30 umol/kg1995Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
(R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl- 2-propynyl]-N-hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor.
AID178503Compound was tested for in vivo inhibition against rat peritoneal anaphylaxis.1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Modulators of leukotriene biosynthesis and receptor activation.
AID18434Oral bioavailability was determined in mouse1995Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
(R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl- 2-propynyl]-N-hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor.
AID24351phase 1 oral half life at a dose 200 mg. (200 mg provided >95% inhibition of ex vivo stimulated LTB4 in blood up to 18 hour post dose)1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Modulators of leukotriene biosynthesis and receptor activation.
AID7057Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells1998Journal of medicinal chemistry, Feb-12, Volume: 41, Issue:4
Design, synthesis, and biological evaluation of conformationally constrained aci-reductone mimics of arachidonic acid.
AID18863Rate of glucuronidation (nmol/min/mg protein) in monkey microsomes1997Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitors.
AID24073t1/2 in monkey after PO dose (2 umol/kg)1997Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitors.
AID181942Percent inhibition of LTE4 formation in rats from peritoneal fluids at a dose of 200 micro mol/Kg1997Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitors.
AID6707In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
5-lipoxygenase inhibitors with histamine H(1) receptor antagonist activity.
AID1724856Metabolic stability in rat liver microsomes assessed as compound remaining after 60 mins2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Design, Synthesis, and Structure-Activity Relationship Studies of Dual Inhibitors of Soluble Epoxide Hydrolase and 5-Lipoxygenase.
AID1724852Inhibition of human sEH (1 to 555 residues) expressed in Escherichia coli BL21-(DE3) using PHOME substrate incubated for 30 to 45 mins by fluorescence based assay2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Design, Synthesis, and Structure-Activity Relationship Studies of Dual Inhibitors of Soluble Epoxide Hydrolase and 5-Lipoxygenase.
AID18435Oral bioavailability in rat1995Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
(R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl- 2-propynyl]-N-hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor.
AID75889Compound was tested for in vivo inhibition against gp antigen bronchospasm.1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Modulators of leukotriene biosynthesis and receptor activation.
AID18430Oral bioavailability was determined in cynomolgus monkey1995Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
(R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl- 2-propynyl]-N-hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor.
AID1553663Suppression of calcium ionophore-stimulated LTB4 production in CAD patient whole blood at 100 mg administered daily during phase 2 study for 12 weeks by ELISA relative to baseline2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Novel Chemical Series of 5-Lipoxygenase-Activating Protein Inhibitors for Treatment of Coronary Artery Disease.
AID1724853Inhibition of 5-LOX (unknown origin) expressed in Escherichia coli BL21-(DE3) pre-incubated for 15 mins before AA substrate addition and measured after 10 mins by HPLC/UV assay2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Design, Synthesis, and Structure-Activity Relationship Studies of Dual Inhibitors of Soluble Epoxide Hydrolase and 5-Lipoxygenase.
AID160513Compound was tested for in vitro inhibition against human PMNL.1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Modulators of leukotriene biosynthesis and receptor activation.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's15 (57.69)18.2507
2000's4 (15.38)29.6817
2010's5 (19.23)24.3611
2020's2 (7.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 15.86

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index15.86 (24.57)
Research Supply Index3.71 (2.92)
Research Growth Index4.39 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (15.86)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials12 (42.86%)5.53%
Reviews1 (3.57%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (53.57%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]